| Literature DB >> 34946681 |
Athanasia Pavlopoulou1,2, Seyedehsadaf Asfa1,2, Evangelos Gioukakis3, Ifigeneia V Mavragani3, Zacharenia Nikitaki3, Işıl Takan1,2, Jean-Pierre Pouget4, Lynn Harrison5, Alexandros G Georgakilas3.
Abstract
Different types of DNA lesions forming in close vicinity, create clusters of damaged sites termed as "clustered/complex DNA damage" and they are considered to be a major challenge for DNA repair mechanisms resulting in significant repair delays and induction of genomic instability. Upon detection of DNA damage, the corresponding DNA damage response and repair (DDR/R) mechanisms are activated. The inability of cells to process clustered DNA lesions efficiently has a great impact on the normal function and survival of cells. If complex lesions are left unrepaired or misrepaired, they can lead to mutations and if persistent, they may lead to apoptotic cell death. In this in silico study, and through rigorous data mining, we have identified human genes that are activated upon complex DNA damage induction like in the case of ionizing radiation (IR) and beyond the standard DNA repair pathways, and are also involved in cancer pathways, by employing stringent bioinformatics and systems biology methodologies. Given that IR can cause repair resistant lesions within a short DNA segment (a few nm), thereby augmenting the hazardous and toxic effects of radiation, we also investigated the possible implication of the most biologically important of those genes in comorbid non-neoplastic diseases through network integration, as well as their potential for predicting survival in cancer patients.Entities:
Keywords: cancer; clustered DNA damage; comorbidities; ionizing radiation; prognosis; systems biology
Mesh:
Substances:
Year: 2021 PMID: 34946681 PMCID: PMC8708251 DOI: 10.3390/molecules26247602
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Workflow illustrating the selection of 44 genes associated with both clustered DNA damage and cellular response to DNA damage, after eliminating genes known to be involved in DDR.
Figure 2Integrated network depicting the top-ranking pairwise relationships (indicated by edges or lines) between genes-neoplasms, and genes and non-neoplastic diseases, derived from DisGeNET; green: genes, magenta: neoplasms, blue: non-neoplastic diseases often appearing as comorbitidies in various types of cancer therapies, like radiation therapies.
Figure 3Kaplan–Meier curves representing the prognostic potential of selected pivotal genes (a) BAX, (b) TNF, (c) BCL2, (d) CCND1, and (e) HMOX1 for overall survival in diverse cancers. The HR “HR(high)” and the corresponding p-values “p(HR)” are shown. The 95% confidence intervals (CI) are indicated by dotted lines. The number of high-risk and low-risk patient groups are denoted by “n(high)” and “n(low),” respectively. An HR value above 1 indicates an increased mortality risk, whereas an HR below 1 denotes a lower risk. Cancer patients with elevated expression of BCL2, CCND1 and HMOX1 may die at a higher rate per unit time of those where the genes BAX and TNF are overexpressed.
List of TCGA cancer types and prognosis-associated with prognosis in the corresponding malignancy.
| Cancer Type * | BAX | TNF | BCL2 | CCND1 | HMOX1 |
|---|---|---|---|---|---|
| Adrenocortical carcinoma (ACC) | x | x | x | x | |
| Bladder urothelial carcinoma (BLCA) | x | x | x | ||
| Breast invasive carcinoma (BRCA) | x | x | x | ||
| Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) | x | x | |||
| Cholangio carcinoma (CHOL) | x | x | x | ||
| Colon adenocarcinoma (COAD) | x | x | x | ||
| Lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) | x | x | x | x | |
| Esophageal carcinoma (ESCA) | x | x | x | ||
| Glioblastoma multiforme (GBM) | x | x | |||
| Head and neck squamous cell carcinoma (HNSC) | x | x | x | ||
| Kidney chromophobe (KICH) | x | x | |||
| Kidney renal clear cell carcinoma (KIRC) | x | ||||
| Kidney renal papillary cell carcinoma (KIRP) | x | x | |||
| Acute myeloid leukemia (LAML) | x | x | |||
| Brain lower grade glioma (LGG) | x | x | |||
| Liver hepatocellular carcinoma (LIHC) | x | x | x | x | |
| Lung adenocarcinoma (LUAD) | x | x | x | x | |
| Lung squamous cell carcinoma (LUSC) | x | x | |||
| Mesothelioma (MESO) | x | x | x | ||
| Ovarian serous cystadenocarcinoma (OV) | x | x | |||
| Pancreatic adenocarcinoma (PAAD) | x | x | x | ||
| Pheochromocytoma and paraganglioma (PCPG) | x | x | x | ||
| Prostate adenocarcinoma (PRAD) | x | x | x | ||
| Rectum adenocarcinoma (READ) | x | x | x | x | |
| Sarcoma (SARC) | x | x | x | ||
| Skin cutaneous melanoma (SKCM) | x | ||||
| Stomach adenocarcinoma (STAD) | x | x | x | ||
| Testicular germ cell tumors (TGCT) | x | x | x | x | |
| Thyroid carcinoma (THCA) | x | x | |||
| Thymoma (THYM) | x | x | x | x | |
| Uterine corpus endometrial carcinoma (UCEC) | x | x | x | x | |
| Uterine carcinosarcoma (UCS) | x | x | x | x | |
| Uveal melanoma (UVM) | x | x | x | x |
* The Cancer Genome Atlas.